001     893884
005     20211018113109.0
024 7 _ |a 10.1111/bjh.17479
|2 doi
024 7 _ |a 0007-1048
|2 ISSN
024 7 _ |a 1365-2141
|2 ISSN
024 7 _ |a 2128/28735
|2 Handle
024 7 _ |a altmetric:105091596
|2 altmetric
024 7 _ |a pmid:33931857
|2 pmid
024 7 _ |a WOS:000646154400001
|2 WOS
037 _ _ |a FZJ-2021-02896
082 _ _ |a 610
100 1 _ |a Taher, Ali T.
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia
260 _ _ |a Oxford [u.a.]
|c 2021
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1633443945_22690
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Bitopertin is a small molecule selective inhibitor of glycine transporter 1 (GlyT1), initially developed to increase brain extracellular levels of glycine in the vicinity of neuronal N-methyl-D-aspartate receptors for the treatment of schizophrenia. GlyT1, the pharmacological target of bitopertin, is also present as a transmembrane transporter in erythroid cells1 and accounts for 50–55% of glycine uptake in human red blood cells (RBCs).2, 3 Erythroid GlyT1 inhibition by bitopertin leads to reduced intracellular glycine availability, interfering with the first step of haem synthesis, in which 5-aminolevulinate synthase catalyses the condensation reaction between glycine and succinyl-coenzyme A, forming 5-aminolevulinic acid.1
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Viprakasit, Vip
|b 1
700 1 _ |a Cappellini, Maria Domenica
|0 0000-0001-8676-6864
|b 2
700 1 _ |a Kraus, Dominik
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Cech, Patrick
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Volz, Dietmar
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Winter, Erica
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Nave, Stephane
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Dukart, Juergen
|0 P:(DE-Juel1)177772
|b 8
700 1 _ |a Khwaja, Omar
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Koerner, Annette
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Hermosilla, Ricardo
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Brugnara, Carlo
|0 0000-0001-8192-8713
|b 12
773 _ _ |a 10.1111/bjh.17479
|g p. bjh.17479
|0 PERI:(DE-600)1475751-5
|n 2
|p 474–481
|t British journal of haematology
|v 194
|y 2021
|x 1365-2141
856 4 _ |u https://juser.fz-juelich.de/record/893884/files/bjh.17479-2.pdf
856 4 _ |y Published on 2021-04-30. Available in OpenAccess from 2022-04-30.
|u https://juser.fz-juelich.de/record/893884/files/DV-BIT74876_Bito_Thal_Letter%20to%20editor_12March2021_JD.pdf
909 C O |o oai:juser.fz-juelich.de:893884
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)177772
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-28
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J HAEMATOL : 2019
|d 2021-01-28
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J HAEMATOL : 2019
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-7-20090406
|k INM-7
|l Gehirn & Verhalten
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-7-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21